Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.
Published in Gut, 2025
Recommended citation: Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M., Bauer, K. C., Huang, P., Ma, C., Monge, C., Xie, C., Hrones, D., Duffy, A. G., Armstrong, P., Kocheise, L., Desmond, F., Buchalter, J., Galligan, M., Cantwell, C., Ryan, R., McCann, J., Bourke, M., Nicholas, R. M., McDermott, R., Awosika, J., Cam, M., Krebs, R., Budhu, A., Revsine, M., Figg, W. D., Kleiner, D. E., Redd, B., Wood, B. J., Wang, X. W., Korangy, F., Claassen, M., & Greten, T. F. (2025). Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut, 74 (6), 983-995.
Download Paper